|Locus||Chr. 9 qter-q12|
|Alt. symbols||H2, RLXH2, bA12D24.1.1, bA12D24.1.2|
|Locus||Chr. 9 qter-q12|
|Alt. symbols||ZINS4, RXN3, H3|
|Locus||Chr. 19 p13.3|
The relaxin-like peptide family belongs in the insulin superfamily and consists of 7 peptides of high structural but low sequence similarity; relaxin-1 (RLN1), 2 (RLN2) and 3 (RLN3), and the insulin-like (INSL) peptides, INSL3, INSL4, INSL5 and INSL6. The functions of relaxin-3, INSL4, INSL5, INSL6 remain uncharacterised.
In the male, it is produced in the prostate and is present in human semen.
Relaxin is produced from its prohormone, "prorelaxin", by splitting off one additional peptide chain.
In females relaxin is produced mainly by the corpus luteum, in both pregnant  and nonpregnant females; it rises to a peak within approximately 14 days of ovulation, and then declines in the absence of pregnancy, resulting in menstruation). During the first trimester of pregnancy, levels rise and additional relaxin is produced by the decidua. Relaxin's peak is reached during the 14 weeks of the first trimester and at delivery. It is known to mediate the hemodynamic changes that occur during pregnancy, such as increased cardiac output, increased renal blood flow, and increased arterial compliance. It also relaxes other pelvic ligaments. It is believed to soften the pubic symphysis.
In males, relaxin enhances motility of sperm in semen.
In other animals
In animals, relaxin widens the pubic bone and facilitates labor; it also softens the cervix (cervical ripening), and relaxes the uterine musculature. Thus, for a long time, relaxin was looked at as a pregnancy hormone. However, its significance may reach much further. Relaxin affects collagen metabolism, inhibiting collagen synthesis and enhancing its breakdown by increasing matrix metalloproteinases. It also enhances angiogenesis and is a potent renal vasodilator.
Relaxin interacts with the relaxin receptor LGR7 (RXFP1) and LGR8 (RXFP2), which belong to the G protein-coupled receptor superfamily. They contain a heptahelical transmembrane domain and a large glycosylated ectodomain, distantly related to the receptors for the glycoproteohormones, such as the LH-receptor or FSH-receptor.
A recombinant form of human relaxin-2 has been developed as investigational drug RLX030 (serelaxin).
- Relaxin family peptide hormones
- Insulin/IGF/Relaxin family
- Relaxin/insulin-like family peptide receptor 1
- Bani D (January 1997). "Relaxin: a pleiotropic hormone.". General pharmacology. 28 (1): 13–22. doi:10.1016/s0306-3623(96)00171-1. PMID 9112071.
- "If a Gopher Can Do It ...". Time Magazine. 1944-04-10. Retrieved 2009-05-20.
- Becker GJ, Hewitson TD (March 2001). "Relaxin and renal fibrosis". Kidney Int. 59 (3): 1184–5. doi:10.1046/j.1523-1755.2001.0590031184.x. PMID 11231378.
- Wilkinson TN, Speed TP, Tregear GW, Bathgate RA (February 2005). "Evolution of the relaxin-like peptide family". BMC Evolutionary Biology. 5: 14. doi:10.1186/1471-2148-5-14. PMC . PMID 15707501.
- MacLennan AH (1991). "The role of the hormone relaxin in human reproduction and pelvic girdle relaxation". Scandinavian journal of rheumatology. Supplement. 88: 7–15. PMID 2011710.
- Conrad KP (August 2011). "Maternal vasodilation in pregnancy: the emerging role of relaxin". Am. J. Physiol. Regul. Integr. Comp. Physiol. 301 (2): R267–75. doi:10.1152/ajpregu.00156.2011. PMC . PMID 21613576.
- Weiss G (February 1989). "Relaxin in the male". Biol. Reprod. 40 (2): 197–200. doi:10.1095/biolreprod40.2.197. PMID 2497805.
- Mookerjee I, Solly NR, Royce SG, Tregear GW, Samuel CS, Tang ML (2006). "Endogenous relaxin regulates collagen deposition in an animal model of allergic airway disease". Endocrinology. 147 (2): 754–61. doi:10.1210/en.2005-1006. PMID 16254028.
- Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, Hsueh AJ (2002). "Activation of orphan receptors by the hormone relaxin". Science. 295 (5555): 674–6. doi:10.1126/science.1065654. PMID 11809971.
- Van Der Westhuizen ET, Summers RJ, Halls ML, Bathgate RA, Sexton PM (2007). "Relaxin receptors--new drug targets for multiple disease states". Curr Drug Targets. 8 (1): 91–104. doi:10.2174/138945007779315650. PMID 17266534.